JP2019523305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523305A5 JP2019523305A5 JP2019526375A JP2019526375A JP2019523305A5 JP 2019523305 A5 JP2019523305 A5 JP 2019523305A5 JP 2019526375 A JP2019526375 A JP 2019526375A JP 2019526375 A JP2019526375 A JP 2019526375A JP 2019523305 A5 JP2019523305 A5 JP 2019523305A5
- Authority
- JP
- Japan
- Prior art keywords
- particle size
- tolucapon
- transthyretin
- malvern
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 description 3
- 206010002022 Amyloidosis Diseases 0.000 description 1
- 206010002023 Amyloidosis Diseases 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010947 wet-dispersion method Methods 0.000 description 1
Description
本発明の第５態様は、トランスサイレチン関連アミロイドーシスの予防及び／又は治療に使用する、上記第１態様の錠剤の形態の医薬組成物に関する。
実施例
トルカポンの粒子サイズの決定
粒子サイズ測定（Ｄv,0.1, Ｄv,0.5, Ｄv,0.9 及び Ｄv,1.0）は、欧州薬局方の２．９．３１節に記載されている一般的方法に従い、具体的には、小体積サンプル用の湿式分散ユニットHYDRO 2000 SMを備える粒子サイズレーザー分析装置 MASTERSIZER 2000（Malvern 社製）を用いて、行うことができる。
トルカポンの粒子サイズの決定
粒子サイズ測定（Ｄv,0.1, Ｄv,0.5, Ｄv,0.9 及び Ｄv,1.0）は、欧州薬局方の２．９．３１節に記載されている一般的方法に従い、具体的には、小体積サンプル用の湿式分散ユニットHYDRO 2000 SMを備える粒子サイズレーザー分析装置 MASTERSIZER 2000（Malvern 社製）を用いて、行うことができる。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382372.7A EP3275433A1 (en) | 2016-07-29 | 2016-07-29 | Sustained release composition comprising micronized tolcapone |
| EP16382372.7 | 2016-07-29 | ||
| PCT/EP2017/069168 WO2018019997A1 (en) | 2016-07-29 | 2017-07-28 | Sustained release composition comprising micronized tolcapone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523305A JP2019523305A (ja) | 2019-08-22 |
| JP2019523305A5 true JP2019523305A5 (ja) | 2020-08-13 |
| JP7047236B2 JP7047236B2 (ja) | 2022-04-05 |
Family
ID=56571284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526375A Active JP7047236B2 (ja) | 2016-07-29 | 2017-07-28 | 微粒子化トルカポンを含む徐放性錠剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11883538B2 (ja) |
| EP (2) | EP3275433A1 (ja) |
| JP (1) | JP7047236B2 (ja) |
| KR (1) | KR102484678B1 (ja) |
| CN (1) | CN109789100A (ja) |
| AU (1) | AU2017303333B2 (ja) |
| CA (1) | CA3032211A1 (ja) |
| DK (1) | DK3490535T3 (ja) |
| ES (1) | ES2891355T3 (ja) |
| MX (1) | MX2019001190A (ja) |
| PT (1) | PT3490535T (ja) |
| RU (1) | RU2750670C2 (ja) |
| WO (1) | WO2018019997A1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024081554A2 (en) * | 2022-10-10 | 2024-04-18 | Corino Therapeutics, Inc. | Modified release tolcapone formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| PL330145A1 (en) | 1996-05-20 | 1999-04-26 | Searle & Co | Pharmaceutic preparations containing sodium and potassum oxaprosin salt as well as that formed from tris |
| CA2326349A1 (en) | 1998-04-09 | 1999-10-21 | F. Hoffmann-La Roche Ag | Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
| US6599530B2 (en) * | 1998-09-14 | 2003-07-29 | Orion Corporation | Oral compacted composition comprising catechol derivatives |
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| US20070218139A1 (en) * | 2002-12-20 | 2007-09-20 | Smith Thomas J | High Pressure Compaction For Pharmaceutical Formulations |
| EP2050447B1 (en) * | 2005-06-08 | 2017-10-11 | Orion Corporation | An entacapone-containing oral dosage form |
| WO2008087882A1 (ja) * | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | 胃内滞留型レボドパ徐放性製剤 |
| ES2776734T3 (es) | 2010-11-15 | 2020-07-31 | Neuroderm Ltd | Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello |
| KR102017354B1 (ko) * | 2011-10-24 | 2019-09-02 | 솜 이노베이션 바이오테크, 에스.엘. | 트랜스타이레틴―관련 아밀로이드증에 대한 신규 치료법 |
| US20130195973A1 (en) * | 2012-01-30 | 2013-08-01 | Ranbaxy Laboratories Limited | Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof |
| CA2904838C (en) * | 2013-03-13 | 2021-03-16 | Neuroderm Ltd. | Method for treatment of parkinson's disease |
| CN113384373B (zh) * | 2013-11-05 | 2022-10-21 | 辛纳吉勒公司 | 经由口腔进行连续药物递送的装置和方法 |
| HUE052857T2 (hu) * | 2014-09-04 | 2021-05-28 | Lobsor Pharmaceuticals Ab | Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei |
-
2016
- 2016-07-29 EP EP16382372.7A patent/EP3275433A1/en not_active Withdrawn
-
2017
- 2017-07-28 KR KR1020197004664A patent/KR102484678B1/ko active IP Right Grant
- 2017-07-28 CN CN201780060604.7A patent/CN109789100A/zh active Pending
- 2017-07-28 PT PT177433588T patent/PT3490535T/pt unknown
- 2017-07-28 JP JP2019526375A patent/JP7047236B2/ja active Active
- 2017-07-28 DK DK17743358.8T patent/DK3490535T3/da active
- 2017-07-28 CA CA3032211A patent/CA3032211A1/en active Pending
- 2017-07-28 US US16/321,336 patent/US11883538B2/en active Active
- 2017-07-28 AU AU2017303333A patent/AU2017303333B2/en active Active
- 2017-07-28 MX MX2019001190A patent/MX2019001190A/es unknown
- 2017-07-28 ES ES17743358T patent/ES2891355T3/es active Active
- 2017-07-28 WO PCT/EP2017/069168 patent/WO2018019997A1/en unknown
- 2017-07-28 RU RU2019103647A patent/RU2750670C2/ru active
- 2017-07-28 EP EP17743358.8A patent/EP3490535B1/en active Active
-
2024
- 2024-01-29 US US18/425,739 patent/US20240216282A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526543A5 (ja) | ||
| WO2014160441A8 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2015081257A5 (ja) | ||
| JP2012143233A5 (ja) | ||
| JP2015525757A5 (ja) | ||
| JP2014237817A5 (ja) | ||
| JP2014530840A5 (ja) | ||
| JP2014022036A5 (ja) | ||
| WO2015023681A3 (en) | Swallowing assessment and improvement systems and methods | |
| JP2016135110A5 (ja) | ||
| WO2016142708A3 (en) | Pharmaceutical composition | |
| JP2014506960A5 (ja) | ||
| AU2014233420A8 (en) | Fine dry particulate retinoid active agent compositions and topical formulations including the same | |
| WO2016140933A3 (en) | Immediate release soluble ibuprofen compositions | |
| JP2019523305A5 (ja) | ||
| CY1121986T1 (el) | Στερεη φαρμακευτικη συνθεση κυtισινης και διαδικασια για την παρασκευη της | |
| JP2019094312A5 (ja) | ||
| WO2016015055A8 (en) | Colon cleansing compositions | |
| WO2013024494A3 (en) | Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone | |
| NZ705930A (en) | A pharmaceutical composition comprising a solid nanoparticle and at least an antigen for the treatment against an intracellular pathogenic agent | |
| JP2014510253A5 (ja) | ||
| EP3535398A4 (en) | DENGUE VIRAL PSEUDO-PARTICLE, ANTIBODIES AGAINST DENGUE VIRUS, AND A PREPARATION INCLUDING IT | |
| JP2016503275A5 (ja) | ||
| JP2015536999A5 (ja) | ||
| JP2016513537A5 (ja) |